Filter Results
Clinical Studies
Results filtered:Study status:
Open
Open
-
A Phase 1/2 Dose Evaluation Trial Of The Safety And Preliminary Efficacy Of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) In Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Rochester, MN
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adult participants with relapsed/refractory primary Immune Thrombocytopenia (ITP) and relapsed/refractory primary Warm Autoimmune Hemolytic Anemia (wAIHA).
-
NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study To Investigate Safety, Tolerability, Pharmacokinetics, And Efficacy Of LY4584180 In Adult Participants With Previously Treated Hematologic Malignancies
Scottsdale/Phoenix, AZ
Rochester, MN
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
-
Phase 2 Trial Of Ulixertinib For Patients With Histiocytic Neoplasms
Rochester, MN
The purpose of this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.
.